Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.
3 Min Read
DEPOSITPHOTOS/Wirestock
Contract development and manufacturing organization (CDMO) National Resilience is constructing a 190,000 square-foot plant in Blue Ash, Ohio. This expansion will support operations at the West Chester plant by adding advanced automation for assembling and packaging drug products filled there. Additionally, the facility includes a cold and ambient storage space.
In partnership with REDI Cincinnati and JobsOhio, Resilience is expecting to create 1000 jobs in the Cincinnati region though its facilities in Blue Ash, and West Chester.
“We are excited to continue our successful partnership with JobsOhio and REDI Cincinnati, as we reach new milestones in expanding our capabilities and impact,” said William Marth, CEO of Resilience. “We’re excited to announce this recent growth, which enhances our expanding drug product manufacturing capabilities in Ohio.”
The San Diego-headquartered company engaged in a three-year contract with REDI Cincinnati and JobsOhio in December 2023. The collaboration aimed to create 440 jobs, following the expansion of its West Chester site.
The 580,000 square-foot West Chester plant has often changed hands. In November 2022, Resilience acquired it from AstraZeneca as part of a deal involving its CDMO services. Prior to this, AstraZeneca had gained the plant in 2013 through its $2.7 billion acquisition of Bristol Myers Squibb’s diabetes business. Bristol Myers Squibb acquired it in 2012 as part of its $5.3 billion purchase of Amylin Pharmaceuticals.
Dan Johnson, economic development director at Blue Ash, said, “We are thrilled to add Resilience to its robust portfolio of life sciences companies. We sincerely appreciate the work of REDI Cincinnati and JobsOhio that actively seek to grow the bio health cluster in this region. It is a testament to our community and its leaders that Blue Ash remains prepared to support the fast-paced growth of an industry leader like Resilience.”
The financials associated with this expansion were not disclosed.
Wheeler Bio
Wheeler Bio is building a 52,000 square-foot biologics manufacturing facility in Oklahoma City. The plant will provide CMC services for antibody-based therapies. It is being constructed next to the CDMO’s biomanufacturing workforce training center (BioTC) in the Oklahoma City Innovation District.
Along with this expansion, Wheeler announced raising $35 million through a Series A-1 financing round by Alloy Therapeutics and Echo Investment Capital (Echo), with participation from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises.
“Wheeler Bio continues to redefine the art of the possible for drug development in the US,” said Christian Kanady, co-founder Wheeler Bio. “This impressive line-up of investors symbolizes both deepened and new partnerships that will be significant as Wheeler accelerates growth and ultimately scales its footprint in Oklahoma City and beyond.”
Patrick Lucy, CEO of Wheeler, stated that the investment will support the company’s growth by accelerating the development of new therapies. “Wheeler’s scientific team and Modular CMC platform coupled with our customer intimate approach is well positioned to enable our partners through clinical and commercial manufacturing.”
SHL Medical
With an investment of $220 million, Swiss CDMO SHL Medical has opened a manufacturing facility in North Charleston, South Carolina. The plant will manufacture autoinjectors for endocrine and metabolic disorders such as glucagon peptide-1 (GLP-1), dermatology, musculoskeletal diseases, and other therapy areas.
The 360,000 square-foot facility has created 300 jobs locally. It includes medical device injection molding technology, and automated assembly capabilities.
“US-based production is a major step forward in our global expansion and reinforces our position as the leader in providing drug delivery solution,” said CEO, SHL Medical, Ulrich Faessler. “With our established site in Taiwan and the upcoming facility in Switzerland, we will be the only autoinjector manufacturer operating across three continents, bringing us even closer to our customers.”
This facility will support the CDMO’s existing operations in Deerfield Beach, Florida. The company expects to deliver 1.5 billion devices to customers in 2025.
"The most trusted autoinjector brand is now made in the US. We are proud to be contributing to the growth of the local economy and becoming a key player in the area while contributing to our sustainability goals.” adds Kimberlee Steele, managing director North America at SHL Medical.
About the Author
You May Also Like
May 12 - May 15, 2025
May 12 - May 15, 2025
BIOPROCESSING MASTERED: Unlock commercial success for mAbs, biologics, and ATMPs. From molecule to market, discover cutting-edge strategies to maximize efficiency, drive innovation, and ensure unparalleled quality at every step of your biopharmaceutical journey.
Learn More
